<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03108703</url>
  </required_header>
  <id_info>
    <org_study_id>052-2015</org_study_id>
    <nct_id>NCT03108703</nct_id>
  </id_info>
  <brief_title>Assessment of QoL and Outcomes With SBRT for RCC</brief_title>
  <acronym>AQuOS-RCC</acronym>
  <official_title>Assessment of Quality of Life and Outcomes in Patients Treated With Stereotactic Body Radiation Therapy (SBRT) for Primary Renal Cell Carcinoma (RCC) - AQuOS-RCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Anand Swaminanth (Co-Principal Investigator), Juravinski Cancer Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stereotactic body radiotherapy (SBRT) is an emerging radiotherapy technique that precisely
      delivers high doses of radiation to tumours. It has been investigated as definitive treatment
      for an increasing variety of primary tumours including lung, liver, prostate, and now renal
      cell carcinoma (RCC). The principal aims of this study are to prospectively assess quality of
      life (QoL) and oncologic outcomes in non-surgical patients who receive SBRT for the treatment
      of RCC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is an evolving body of literature that shows high rates of tumour control and minimal
      associated toxicities with SBRT to treat RCC. However, the majority of published evidence is
      retrospective in nature, and there is a scarcity of data on the impact on quality of life and
      cost-effectiveness of kidney SBRT.

      The principal aims of this multicentre study are to prospectively assess QoL and oncologic
      outcomes in non-surgical patients who receive SBRT for the treatment of primary renal cell
      carcinoma.

      The study population will include 30 consecutive patients treated with kidney SBRT on a
      conventional linear accelerator (35-40 Gy in 5 fractions) at the Odette Cancer Centre,
      Sunnybrook Health Sciences Centre, University of Toronto (OCC) and the Juravinski Cancer
      Center, Hamilton Health Sciences Centre, McMaster University (JCC).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Up to 5 years after treatment</time_frame>
    <description>To evaluate quality of life scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost-Effectiveness</measure>
    <time_frame>Up to 5 years after completion of treatment</time_frame>
    <description>To assess health utility scores and correlate with QoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oncologic Outcomes</measure>
    <time_frame>Up to 5 years after completion of treatment</time_frame>
    <description>To evaluate local control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oncologic Outcomes</measure>
    <time_frame>Up to 5 years after completion of treatment</time_frame>
    <description>To evaluate progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oncologic Outcomes</measure>
    <time_frame>Up to 5 years after completion of treatment</time_frame>
    <description>To evaluate overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Up to 5 years after completion of treatment</time_frame>
    <description>To report number of participants with treatment-related toxicities as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RCC patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>35-40 Gy delivered in 5 fractions</description>
    <arm_group_label>SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥18 years old

          -  Medically inoperable or patient who refuses surgery

          -  Histologic diagnosis of RCC where possible, or radiologic evidence of growth on
             surveillance

          -  Lesion ≥2.5cm or recurrent lesion following local ablative therapy

          -  Written informed consent

          -  Participants must be able to understand the English-language or with the aid of a
             translator

        Exclusion Criteria:

          -  ECOG ≥3

          -  Prior abdominal radiation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>William Chu, MD</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>7086</phone_ext>
    <email>william.chu@sunnybrook.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Darby Erler, MHSc</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>7844</phone_ext>
    <email>darby.erler@sunnybrook.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anand Swaminath, MD</last_name>
      <phone>905-387-9711</phone>
      <phone_ext>63123</phone_ext>
      <email>swaminath@hhsc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre, Sunnybrook Health Science Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Chu, MD</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>7086</phone_ext>
      <email>william.chu@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Darby Erler, MHSx</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>7844</phone_ext>
      <email>darby.erler@sunnybrook.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2017</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sunnybrook Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Dr. William Chu</investigator_full_name>
    <investigator_title>Radiation Oncologist</investigator_title>
  </responsible_party>
  <keyword>RCC</keyword>
  <keyword>Stereotactic Body Radiotherapy</keyword>
  <keyword>SBRT</keyword>
  <keyword>Stereotactic Ablative Radiotherapy</keyword>
  <keyword>SABR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

